Lipocine Inc
Company Overview
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oral drug delivery systems for treatments related to metabolic and endocrine disorders. The company's primary focus is on developing oral testosterone replacement therapies and other products for conditions such as liver disease and obesity.
The company's lead product candidate is TLANDO, an oral testosterone replacement therapy that received FDA approval. They also have other pipeline products in development including LPCN 1144 for the treatment of liver disease and LPCN 1148 for cirrhosis.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| June 30, 2024 | $89565.0 | $3.38m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $7.62m | $4.39m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Lipocine Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.